68
Participants
Start Date
February 28, 2003
Primary Completion Date
February 28, 2007
Study Completion Date
December 31, 2016
cisplatin
100 mg/m\^2 intravenously on days 1, 22, and 43 and 80 mg/m\^2 intravenously on days 71, 99, and 127
fluorouracil
1000 mg/m\^2/day as 96-hour continuous infusion on days 71-74, 99-102, and 127-130
Intensity modulated radiation therapy
The gross tumor and lymph node metastasis, Planning Target Volume (PTV) 70 (Clinical Target Volume \[CTV\] 70 with a 5 mm margin) will receive 70 Gy in 33 fractions at 2.12 Gy per fraction. Treatment will be delivered once daily, 5 fractions per week, over 6 weeks and 3 days.
CCOP - MainLine Health, Wynnewood
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia, Philadelphia
Northeast Georgia Medical Center, Gainesville
Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham
Akron City Hospital, Akron
Medical College of Wisconsin Cancer Center, Milwaukee
Mayo Clinic Cancer Center, Rochester
Siteman Cancer Center at Barnes-Jewish Hospital, St Louis
M.D. Anderson Cancer Center at University of Texas, Houston
Wilford Hall Medical Center, Lackland Air Force Base
McKay-Dee Hospital Center, Ogden
Albuquerque Regional Medical Center at Lovelace Sandia Health System, Albuquerque
UCSF Comprehensive Cancer Center, San Francisco
University of California Davis Cancer Center, Davis
Radiological Associates of Sacramento Medical Group, Incorporated, Sacramento
Monmouth Medical Center, Long Branch
Fox Chase-Temple Cancer Center, Philadelphia
National Cancer Institute (NCI)
NIH
Radiation Therapy Oncology Group
NETWORK